The task force will be charged with researching the reasons certain shortages are persistent and finding holistic solutions to address the causes of the shortages.
The group, which will expand on the work of a group created by the FDA’s Safety and Innovation Act of 2012, will be led by Keagan Lenihan, the FDA’s associate commissioner for strategic initiatives.
To ensure holistic solutions, the group will tap senior leaders from the FDA, CMS and the Department of Veterans affairs.
More articles on pharmacy:
Packaging concerns force Novartis, Sandoz to recall 12 drugs
Pfizer stock value dips after Trump’s tweet
8 lesser-known facts about Pfizer
